Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-09-04
2007-09-04
Marschel, Ardin H. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S962000, C424S451000, C424S464000
Reexamination Certificate
active
10637820
ABSTRACT:
Use of escitalopram (the S-(+)-enantiomer of citalopram) or a pharmaceutically acceptable salt thereof for the preparation of a medicament useful in the treatment of neurotic disorders is provided, including anxiety states, in particular generalised anxiety disorder and social anxiety disorder, post traumatic stress disorder, obsessive compulsive disorder and panic attacks.
REFERENCES:
patent: 3467675 (1969-09-01), Peterson et al.
patent: 4136193 (1979-01-01), Bogeso et al.
patent: 4650884 (1987-03-01), Bogeso et al.
patent: 4902710 (1990-02-01), Foster et al.
patent: 4943590 (1990-07-01), Boegesoe et al.
patent: 4962128 (1990-10-01), Doogen et al.
patent: 5114976 (1992-05-01), Norden
patent: 5296507 (1994-03-01), Tanaka et al.
patent: RE34712 (1994-08-01), Boegesoe et al.
patent: 5627196 (1997-05-01), Hibschman et al.
patent: 5648396 (1997-07-01), Young et al.
patent: 5788986 (1998-08-01), Dodman
patent: 5958429 (1999-09-01), Wong
patent: 5962514 (1999-10-01), Evenden et al.
patent: 6069177 (2000-05-01), Carlier et al.
patent: 6147072 (2000-11-01), Bymaster et al.
patent: 6159971 (2000-12-01), Berg et al.
patent: 6169105 (2001-01-01), Wong et al.
patent: 6184219 (2001-02-01), Evenden et al.
patent: 6333357 (2001-12-01), Eig
patent: 6469064 (2002-10-01), Druzgala
patent: 2002/0103249 (2002-08-01), Lundbeck
patent: 0 347 066 (1989-12-01), None
patent: 0474580 (1992-03-01), None
patent: 0714663 (1996-06-01), None
patent: 0759299 (1997-02-01), None
patent: 0 814 08 (1997-12-01), None
patent: WO-92/18005 (1992-10-01), None
patent: WO-93/09769 (1993-05-01), None
patent: WO-96/24353 (1996-08-01), None
patent: WO-99/14207 (1999-03-01), None
patent: WO-00/02551 (2000-01-01), None
patent: WO-00/03701 (2000-01-01), None
patent: WO-00/15219 (2000-03-01), None
patent: WO-00/15220 (2000-03-01), None
patent: WO-00/34263 (2000-06-01), None
patent: WO-01/03694 (2001-01-01), None
patent: WO-01/54681 (2001-08-01), None
Celexa for the treatment of depression Medical Sciences Bulletin 21 1998.
Hytell, J., Prog. Neuro-Psychopharmocol. & Biol. Psychiat., 1982, 6, 277-295.
Gravem, A., Acta Psychiatr. Scand., 1987, 75, 478-486.
Sanchez, C., Effect of serotonergic drugs on footshock-induced ultrasonice vocalization in adult male rats, Behav. Pharmacol. 1993; 4;267-277.
Sanchez, C., Pharmacol. Toxicol. 77, 71-78 (1995).
A.F. Joubert et al., “Citalopram and Anixety Disorders,” Rev. Contemp. Pharmacither 10: 79-131 (1999).
Ulla M. Lepola et al., “A Controlled Perspective, 1—Year Trial of Citalopram in the Treatment of Panic Disorder,” J. CLin. Psychiatry 59, 10: 528-534 (1998).
H. Koponen et al., “Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study,” Acta Psychiatrica Scandinavica 96:343-346 (1997).
Dan J. Stein et al, “Use of serotonin selective reuptake inhibitor citalopram in obsessive-compulsive disorder,” Journal of Serotonin Research 1: 29-33 (1996).
Bigler, Allan et al., “Quantitative Struacture-activity Relationships in a Series of Selective 5-HT uptake inhibitors,” Eur. J. Med. Chem. 3:289-295 (1997).
Soraya Seedat et al., “Open Trial of Citalopram in adults with post-tramatic stress disorder,” International Journal of Neuropsychopharmacology 3: 135-140 (2000).
Ihoko Muraki et al., “Effect of subchronic lithium carbonate treatement on anxiolytic-like effect of citalopram and MKC-242 in conditioned fear stress in the rat,” European Journal of Pharmacology 383:223-229 (1999).
Jennifer Y. Tan et al, “Citalopram in the Treatment of Depression and Other Potential Uses in Psychiatry,” Pharmacotherapy 19, 6: 375-689 (1999).
Mario Amore et al., “Short-term and Long-term evaluation of Selective Serotonin Reuptake Inhibitors in the Treatment of Panic Disorder: Florxetine vs. Citalopram,” Hum. Psychopharmacol. Clin. Exp. 14: 435:440 (1999).
Emanuela Mundo, M.D. et al., “Efficacy of Fluvoxamine, Paroxetine, and Citalopram in the Treatment of Obsessive-Compulsive Disorder: A Single-Blind Study,” Journal of Clinical Psychopharmacology 17, 4: 267-271 (Aug. 1997).
Zoltan Rihmer, “Successful treatment of salbutamol-induced panic disorder with citalopram,” European Neuropsychopharmacology 7:241-242 (1997).
Takeshi Inoue et al., “Effect of italopram, a selective serotonin reuptake inhibitor, on the acquisition of conditioned freezing,” European Journal of Pharmacology 311: 1-6 (1996).
U. Lepola et al., “Citalopram in the Treatment of Early-onset Panic Disorder and School Phobia,” Pharmacopsychiatry 29: 30-32 (Jan. 1996).
J. Hyttel et al., “The Pharmacology of Citalopram,” Rev. Contemp. Pharmacother. 6: 271-285 (1995).
American Psychiatric Associations, “DSM-IV” (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition): 393-444 (1994).
Humble, M., et al., “Serotonin, Panic Disorder and Agoraphobia: Short-Term and Long-Term Efficacy of Citalopram in Panic Disorders”, International Clinical Psychopharmacology, 1992, vol. 6, No. suppl 5, pp. 21-39.
Sanchez, Connie, et al., “Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression”, Psychopharmacology, 1997, vol. 129, pp. 197-205.
Bouwer, C., et al., “Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia”, Journal of Affective Disorders, Apr. 1998, vol. 49, No. 1, pp. 79-82.
Lepola U., et al., “Citalopram in the Treatment of Social Phobia: A Report of Three Cases”, Pharmacopsychiatry, Sep. 1994, vol. 27, No. 5, pp. 186-188.
Hyttel, J., et al., “The pharmacological effect of citalopram resides in the (S)—(+)-enantiomer”, Journal of Neural Transmission, 1992, vol. 88, No. 2, pp. 157-160.
Sanchez, C., R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalisation model, European Journal of Pharmacology, 464, 2003, pp. 155-158.
Sanchez, C., Stress-induced vocalisation in adult animals: A valid model of anxiety?, European Journal of Pharmacology, 463 (2003) 133-143.
Wade, A. e t al., Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression i primary care, International Clinical Psychopharmacology 2002, vol. 17 No. 3.
Sackeim, H.A., The definition and meaning of treatment-resistant depression, J. Clin. Psychiatr 2001, 62 Suppl 16, 10-17.
Nierenber, A.A. and DeCecco, L.M., Definitions of antidepressant treatment response, remission, non-response, partial response, and other relevant outcomes: A focus on treatment-resistant depression, J. Clin. Psychiatr 2001, 62 Suppl 16, 5-9.
Kornstein, S.C. and Schneider, R.K., Clinical features of treatment-resistant depression, J. Clin. Psychiatr 2001, 62 Suppl, 18-25.
Willner, P., Psychopharmacology, 1997, 134, 319-329.
Stahl, et al., J. Clin. Psychiatry 2003; 64: 1322-1327.
Burke, W., et al., Fixed-Dose Trial of the Single Isomer SSRI Escitalopram in Depressed Outpatients, J. Clin Psychiatry, 63: Apr. 4, 2002.
Montgomery S. et al., Escitalopram (S-Enantiomer of Citalopram): Clinical Efficacy and Onset of Action Predicted from a Rat Model. Pharmacology & Toxicology, 2001, 88, 282-286.
Montgomery, S.A., et al., “The antidepressant efficacy of citalopram”, International Clinical Psychopharmacology (1996), vol. 11, Supplement 1, pp. 29-33.
Bouchard, J.M., et al., “Citalopram and Viloxazine in the treatment of depression by means of slow drop infusion: A double-blind comparative trial”, Journal of Affective Disorders, vol. 46, pp. 51-58 (1997).
Poster, Escitalopram and Paroxetine in Fixed Doses for the Treatment of Social Anxiety Disorder (SAD), Presented at the 44thAnnual Meeting of the Scandinavian College of Neuro-Psychopharmacology, Apr. 9-12, 2003, Juan-les-Pins, France, 1 page.
Siegfried Kasper et al., “Escitalopram is Efficacious and well Tolerated in the Treatment of Social Anxiety Disorder”, ADAA Nati
Hogg Sandra
Sanchez Connie
Darby & Darby
Gembeh Shirley V.
H. Lundbeck A/S
Marschel Ardin H.
LandOfFree
Treatment of neurotic disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of neurotic disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of neurotic disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3795076